Treating AML in children with Down syndrome
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a treatment plan for children with Down syndrome who have been diagnosed with acute myeloid leukemia (AML) or a related bone marrow condition. The goal is to see how well the therapy works and to help guide doctors in choosing the best approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 0 and 18 years old
- You have been diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
- You have Down syndrome (confirmed by trisomy 21 and a GATA1 gene change)
- Your parent or guardian has signed an informed consent form
- You have not already received more than 14 days of strong chemotherapy for this condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
This trial offers a personalized treatment plan for children with hard-to-treat or relapsed acute myeloid leukemia (AML). The plan is based on the unique genetic makeup of the child's cancer and lab tests that find the most effective drugs.
This study tests a treatment plan for children under 18 with a new diagnosis of acute myeloid leukemia (AML). It aims to provide effective therapy based on standard guidelines, and may include children with certain blood or bone marrow findings even if tests are limited.
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.